ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI ®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients ...

ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients ...

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI ®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients ...

(HealthDay News) — For patients undergoing elective carotid artery stenting (CAS), stroke/death rates are similar with use of proximal embolic protection devices (P-EPDs) and distal filter embolic ...

"The reasons for these findings likely represent our lack of a complete understanding of the factors involved in no-reflow/distal embolization phenomena." The use of a distal embolic protection device ...

Elective carotid artery angioplasty and stenting was initiated in the United States in 1994 by the endovascular interventional team at the University of Alabama at Birmingham. Carotid stenting was ...

DUBLIN, April 18, 2023 /PRNewswire/ -- The "Embolic Protection Device Market, Global Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been ...

MILAN, March 15, 2017 /PRNewswire/ -- Innovative Cardiovascular Solutions (ICS), a privately held medical device company pioneering novel solutions for embolic protection during transcatheter aortic ...

€2.1M Grant to support Filterlex's CAPTIS clinical trials YOKNEAM, Israel, Sept. 16, 2019 /PRNewswire/ -- Filterlex Medical, an innovative medical device startup in the cardiovascular field, today ...

Recently published research shows that a medical device may be beneficial for patients who have previously had a stroke and are planning to undergo a transcatheter aortic valve replacement, a type of ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...